Evidence map›Paper›PMID 40640409›Full record

ArticleCardiovascular and interventional radiology2025

Tumor Dose as an Oncologic Predictor of Outcome in Patients with HCC Treated with Resin Y90 Microspheres.

Howard Dabbous, Sandra Gad, Michael Mohnasky, Alex Villalobos, David Brandon, Minzhi Xing, Nima Kokabi

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Howard DabbousDepartment of Radiology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Sandra GadDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Dr, Chapel Hill, NC, 27514, USA.
Michael MohnaskySchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alex VillalobosDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Dr, Chapel Hill, NC, 27514, USA.
David BrandonDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Minzhi XingGillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nima KokabiDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Dr, Chapel Hill, NC, 27514, USA. Nima_kokabi@med.unc.edu.ORCID http://orcid.org/0000-0002-4569-2720

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate tumor dose (TD) as a predictor of oncological outcomes in patients with hepatocellular carcinoma (HCC) treated with resin Y90 radioembolization (RE), and to evaluate non-tumoral liver dose (NTLD) as a predictor of treatment-related toxicity.

methodsA single-center retrospective review of treatment-naïve HCC patients who underwent resin-based Y90 between 2019 and 2022 was conducted. Baseline demographics, clinical history, and adverse events per CTCAE v5.0 were analyzed. Baseline imaging and post-treatment imaging were also evaluated using Response per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for tumor response.

results78 patients (mean age:66.7 years) with 91 tumors underwent Y90-RE, with a median follow-up period of 28.3 months; 23 received lobar Y90-RE, while 55 patients received segmentectomies. Mean TD for the entire cohort was 336.6 ± 291.9 Gy. Mean TD was significantly higher in segmental Y90-RE (424.3 Gy) vs lobar Y90-RE (203.7 Gy) (p < 0.001). At 3 months, 98% of segmentectomy and 72% of lobar patients achieved an objective response (OR), with 90% and 40% achieving complete response (CR), respectively. At 6 months, 97% and 94% of segmentectomy patients achieved OR and CR, compared to 84% and 68% in lobar patients. Mean tumor dose > 250 Gy predicted prolonged overall and progression free survival. A mean NTLD dose of 103 Gy predicted grade 3 + adverse events in lobar treatments.

conclusionIn patients with HCC treated with resin-based Y90-RE, personalized dosimetry is a key factor in ensuring favorable oncological outcomes. Level of evidence Level 3b, retrospective cohort study.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsYttrium RadioisotopesAgedFemaleHumansMaleMicrospheresMiddle AgedRadiotherapy DosageRetrospective StudiesTreatment OutcomeYttrium-90Yttrium RadioisotopesHepatocellular carcinoma (HCC) resin Y90 radioembolization (RE)Non-tumoral liver dose (NTLD)RadioembolizationTumor Dose (TD)Y-90

Identifiers

PMID40640409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.